Literature DB >> 16558049

Immunochemical Studies of Two Cholera Toxin-Containing Standard Culture Filtrate Preparations of Vibrio cholerae.

J Holmgren1, I Lönnroth, O Ouchterlony.   

Abstract

Two crude toxin preparations of Vibrio cholerae, labeled lot 4493 G (Inaba) and lot 001 (Ogawa), consisting of freeze-dried culture filtrate, were studied with regard to toxicity, precipitinogenicity, and chemical composition. Lot 4493 G contained much more carbohydrate and less protein than lot 001, but both of the preparations contained three precipitinogens which were identical. One of these factors was identified as cholera exotoxin. In addition, both contained a fourth cross-reacting precipitinogen related to lipopolysaccharide. The toxicity of the lots was very similar. The toxin active as permeability factor in the intradermal test, identified completely in comparative double-diffusion analyses with the toxin causing cholera-like symptoms in experimental animals, strongly indicated that the same toxin molecule was active in the two different model systems. The isoelectric point of the toxin was about pH 7, but some toxic activity focused toward a pH of 9. The toxicity was completely retained by a UM-10 membrane (cut at a molecular weight of 10,000), practically retained by a PSED membrane (cut at a molecular weight of 25,000), but not retained by an XM-50 membrane (cut at a molecular weight of 50,000). By gel filtration through agarose, it was possible to separate and purify more than 1,000-fold the toxin from the other, more rapidly filtering three precipitinogens. With lot 4493 G, the toxicity of the agarose gel filtration fractions was restricted to an elution volume similar to that of globular proteins with a molecular weight of 25,000 to 38,000, whereas gel filtration experiments through Sephadex G-75 indicated a size of the toxin corresponding to a molecular weight of about 55,000 to 60,000.

Entities:  

Year:  1971        PMID: 16558049      PMCID: PMC416232          DOI: 10.1128/iai.3.6.747-755.1971

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Experimental cholera. A canine model.

Authors:  R B Sack; C C Carpenter; R W Steenburg; N F Pierce
Journal:  Lancet       Date:  1966-07-23       Impact factor: 79.321

Review 2.  Cholera toxins.

Authors:  W Burrows
Journal:  Annu Rev Microbiol       Date:  1968       Impact factor: 15.500

3.  Pathogenesis of experimental cholera: biologic ativities of purified procholeragen A.

Authors:  R A Finkelstein; P Atthasampunna; M Chulasamaya; P Charunmethee
Journal:  J Immunol       Date:  1966-03       Impact factor: 5.422

4.  Comparative testing of precipitation methods for quantitation of C-reactive protein in blood serum.

Authors:  L A Nilsson
Journal:  Acta Pathol Microbiol Scand       Date:  1968

5.  Antitoxic immunity in experimental canine cholera.

Authors:  G T Curlin; J P Craig; A Subong; C C Carpenter
Journal:  J Infect Dis       Date:  1970-05       Impact factor: 5.226

Review 6.  The determination of nitrogen in biological materials.

Authors:  S Jacobs
Journal:  Methods Biochem Anal       Date:  1965

7.  Production of highly purified choleragen and choleragenoid.

Authors:  R A Finkelstein; J J LoSpalluto
Journal:  J Infect Dis       Date:  1970-05       Impact factor: 5.226

8.  Cholera toxins: purification and preliminary characterization of ileal loop reactive type 2 toxin.

Authors:  W H Coleman; J Kaur; M E Iwert; G J Kasai; W Burrows
Journal:  J Bacteriol       Date:  1968-10       Impact factor: 3.490

9.  Serological studies in cholera. 3. Serum toxin neutralization--rise in titre in response to infection with Vibrio cholerae, and the level in the "normal" population of East Pakistan.

Authors:  A S Benenson; A Saad; W H Mosley; A Ahmed
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

10.  Pathogenesis of experimental cholera. Preparation and isolation of choleragen and choleragenoid.

Authors:  R A Finkelstein; J J LoSpalluto
Journal:  J Exp Med       Date:  1969-07-01       Impact factor: 14.307

View more
  8 in total

1.  Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid.

Authors:  A M Svennerholm; J Holmgren
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

2.  Experimental studies on cholera immunization. II. Evidence for protective antitoxic immunity mediated by serum antibodies as well as local antibodies.

Authors:  J Holmgren; A Andersson; G Wallerstrom; O Ouchterlony
Journal:  Infect Immun       Date:  1972-05       Impact factor: 3.441

3.  Partial purification and properties of somatic antigen spontaneously released from Vibrio cholerae.

Authors:  R M Pike; C H Chandler
Journal:  Infect Immun       Date:  1975-07       Impact factor: 3.441

4.  Enzyme-linked immunosorbent assays for cholera serology.

Authors:  J Holmgren; A M Svennerholm
Journal:  Infect Immun       Date:  1973-05       Impact factor: 3.441

5.  Antitoxic immunity in experimental cholera: protection, and serum and local antibody responses in rabbits after enteral and parenteral immunization.

Authors:  J Holmgren; A M Svennerholm; O Ouchterlony; A Anderson; G Walletström; U Westerberg-Berndtsson
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

6.  Protection against challenge with Escherichia coli heat-labile enterotoxin by immunization of rats with cholera toxin/toxoid.

Authors:  N F Pierce
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

7.  Comparison of the tissue receptors for Vibrio cholerae and Escherichia coli enterotoxins by means of gangliosides and natural cholera toxoid.

Authors:  J Holmgren
Journal:  Infect Immun       Date:  1973-12       Impact factor: 3.441

8.  Immunoglobulin and specific-antibody synthesis in vitro by enteral and nonenteral lymphoid tissues after subcutaneous cholera immunization.

Authors:  A M Svennerholm; J Holmgren
Journal:  Infect Immun       Date:  1977-02       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.